Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekt og sikkerhed af selumetinib hos voksne med NF1, der har symptomatiske, inoperable plexiforme neurofibromer (KOMET)

20. oktober 2026 opdateret af: AstraZeneca

Et fase III, multicenter, internationalt studie med et parallelt, randomiseret, dobbeltblindt, placebokontrolleret, 2-armsdesign for at vurdere effektiviteten og sikkerheden af ​​selumetinib hos voksne deltagere med NF1, som har symptomatiske, inoperable plexiforme neurofibromer (KOMET)

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a randomized, double-blind, placebo-controlled, 2 arm multicentre, global Phase III study to assess the efficacy and safety of selumetinib compared with placebo in adult participants with NF1 who have symptomatic, inoperable PN.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

145

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Melbourne, Australien, 3000
        • Research Site
      • St Leonards, Australien, 2065
        • Research Site
      • Porto Alegre, Brasilien, 90035-903
        • Research Site
      • Ribeirão Preto, Brasilien, 14051-140
        • Research Site
      • São Paulo, Brasilien, 045202-001
        • Research Site
    • Ontario
      • Toronto, Ontario, Canada, M5G 2C4
        • Research Site
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Research Site
      • London, Det Forenede Kongerige, SE1 9RT
        • Research Site
      • Manchester, Det Forenede Kongerige, M20 4BX
        • Research Site
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • Research Site
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20852
        • Research Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63156
        • Research Site
    • New York
      • Commack, New York, Forenede Stater, 11725
        • Research Site
      • Créteil, Frankrig, 94000
        • Research Site
      • Lyon, Frankrig, 69008
        • Research Site
      • Toulouse, Frankrig, 31059
        • Research Site
      • Milan, Italien, 20133
        • Research Site
      • Naples, Italien, 80131
        • Research Site
      • Roma, Italien, 00165
        • Research Site
      • Minatoku, Japan, 105-8471
        • Research Site
      • Nagoya, Japan, 466-8560
        • Research Site
      • Shinjuku-ku, Japan, 160-8582
        • Research Site
      • Beijing, Kina, 100070
        • Research Site
      • Beijing, Kina, 100730
        • Research Site
      • Guangzhou, Kina, 510060
        • Research Site
      • Shenyang, Kina, 110001
        • Research Site
      • Bydgoszcz, Polen, 85-094
        • Research Site
      • Moscow, Rusland, 115522
        • Research Site
      • Moscow, Rusland, 125412
        • Research Site
      • Badalona, Spanien, 08916
        • Research Site
      • Madrid, Spanien, 28041
        • Research Site
      • Hamburg, Tyskland, 20246
        • Research Site
      • Tübingen, Tyskland, 72076
        • Research Site
      • Würzburg, Tyskland, 97080
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Adults ≥ 18 years at enrollment with diagnosis of NF1 with symptomatic, inoperable PN
  • At least one inoperable target PN measurable by volumetric MRI analysis
  • Chronic target PN pain score documented for minimum period during screening period
  • Stable chronic PN pain medication use at enrollment
  • Adequate organ and marrow function

Key Exclusion Criteria:

  • Confirmed or suspected malignant glioma or MPNST (low grade glioma, including optic glioma not requiring systemic therapy or radiation therapy are exempt from this exclusion)
  • History of malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence
  • Clinically significant cardiovascular disease, including inherited coronary disease, acute coronary syndrome within 6 months prior to enrollment, uncontrolled angina, symptomatic heart failure, cardiomyopathy, severe valvular heart disease, abnormal LVEF and uncontrolled hypertension
  • Ophthalmological findings/conditions including intraocular pressure > 21 mmHg, RPED/CSR or RVO
  • Prior exposure to MEK inhibitors

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A

Selumetinib

Selumetinib oral capsules (10 mg and 25 mg)

Andre navne:
  • AZD6244
Placebo komparator: Arm B

Placebo

Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN.
Tidsramme: From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days)

Objective response rate is defined as the proportion of participants who have a confirmed CR (defined as disappearance of the target PN, confirmed by a consecutive scan within 3 to 6 months after the first response) or confirmed PR (defined as a target PN volume decrease ≥ 20%, compared to baseline, confirmed by a consecutive scan within 3 to 6 months after the first response) by end of Cycle 16 as determined by ICR per REiNS criteria.

Increase in the volume of the target PN by 20% or more compared to baseline or the time of best response after documenting a PR is considered as PD.

From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
(First Key Secondary) The Difference of the Means in the Change From Baseline in PAINS-pNF Chronic Target PN Pain Intensity Score at Cycle 12 Between Selumetinib and Placebo, Primary Analysis
Tidsramme: Baseline and end of cycle 12 of study intervention

The PAINS-pNF (Pain Intensity Scale for Plexiform Neurofibroma) chronic target PN pain intensity measures the participants' experience of chronic PN-related pain intensity with score from 0 (no chronic tumor pain) to 10 (worst chronic tumor pain). Baseline PAINS-pNF chronic target PN pain score is defined as the average of the available daily PAINS-pNF chronic target PN pain scores in the screening perio, while for Cycle 12, it is defined as the average of the available daily scores for the 28-days cycle up to and including the last day assessment of cycle 12. The difference of the means in the change from baseline at Cycle 12 between selumetinib and placebo in participants with a PAINS-pNF chronic target PN pain score of ≥ 3 at baseline is presented.

Baseline and end of cycle 12 of study intervention
(First Key Secondary) The Difference of the Means in the Change From Baseline in PAINS-pNF Chronic Target PN Pain Intensity Score at Cycle 12 Between Selumetinib and Placebo, Supplemental Analysis
Tidsramme: Baseline and end of cycle 12 of study intervention

The PAINS-pNF (Pain Intensity Scale for Plexiform Neurofibroma) chronic target PN pain intensity measures the participants' experience of chronic PN-related pain intensity with score from 0 (no chronic tumor pain) to 10 (worst chronic tumor pain). Baseline PAINS-pNF chronic target PN pain score is defined as the average of the available daily PAINS-pNF chronic target PN pain scores in the screening period, while for Cycle 12, it is defined as the average of the available daily scores for the 28-days cycle up to and including the last day assessment of cycle 12. The difference of the means in the change from baseline at Cycle 12 between selumetinib and placebo participants is presented.

Baseline and end of cycle 12 of study intervention
(Second Key Secondary Endpoint) The Difference of the Means in the Change From Baseline in PlexiQoL Total Score at Cycle 12
Tidsramme: Baseline and end of Cycle 12 of study intervention

PlexiQoL (Plexiform Neurofibroma Quality of Life scale) is a patient-derived QoL measure specific to adults with NF1-associated PNs. It assesses the impact of PNs on patients' ability to fulfil their human needs. The measure consists of 18 dichotomous items with 0 =Not True and 1 = True. PlexiQoL total scores were calculated by the sum of all items to a maximum of 18, with lower scores indicating better quality of life. The change from baseline to the end of each cycle in PlexiQoL total score was derived as the PlexiQoL total score at the cycle 12 minus baseline PlexiQoL total score and presented.

Baseline and end of Cycle 12 of study intervention
Confirmed Partial and Complete Response Rate (ORR) Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN (Single Arm)
Tidsramme: From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)

Objective response rate is defined as the proportion of participants who have a confirmed CR (defined as disappearance of the target PN, confirmed by a consecutive scan within 3 to 6 months after the first response) or confirmed PR (defined as a target PN volume decrease ≥ 20%, compared to baseline, confirmed by a consecutive scan within 3 to 6 months after the first response) by end of study (final DCO) as determined by ICR per REiNS criteria. Increase in the volume of the target PN by 20% or more compared to baseline or the time of best response after documenting a PR is considered as PD.

From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)
Duration of Response by Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) (Single Arm)
Tidsramme: From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)

The duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression by ICR per REiNS criteria or death due to any cause. Duration of response is derived using while on-treatment MRI volumetric assessments. The percentage of participants with event are provided.

From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)
Progression Free Survival (PFS) Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) (Single Arm)
Tidsramme: From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)

Progression free survival (PFS) is the time from randomisation date until the date of progression by ICR per REiNS criteria or death due to any cause, or last evaluable MRI assessment for subjects that do not progress. For subjects that progress after two or more consecutive missed MRI assessments, the subject is censored at the time of the latest evaluable MRI assessment prior to the missed visits. The percentage of participants with event are provided.

From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)
Time to Progression (TTP) Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) (Single Arm)
Tidsramme: From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)

Time to progression (TTP) is the time from randomisation date until the date of first documented objective disease progression by ICR per REiNS criteria, or last evaluable MRI assessment for subjects that do not progress. For subjects that progress after two or more consecutive missed MRI assessments, the subject is censored at the time of the latest evaluable MRI assessment prior to the missed visits. The percentage of participants with event are provided.

From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)
Time to Response (TTR) Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) (Single Arm)
Tidsramme: From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)

Time to response (TTR) is the time from randomisation date until the date of first documented objective partial and complete response (which is subsequently confirmed, cCR or cPR) as determined by ICR per REiNS criteria. Only participant who have achieved a cCR or a cPR are evaluated for TTR.

From 1st dose until progression (if before final DCO) or last evaluable assessment up to the last assessment prior to final DCO (up to 3y 3mo from 1st dose), excluding MRI during prolonged study intervention interruption (interruption >=28 days)
Best Percentage Change From Baseline (PCHG) in Target PN During Randomized Period
Tidsramme: From randomisation date until end of cycle 12 of study intervention

The best change in volume is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction and includes all on-treatment MRI volumetric assessments by the end of Cycle 12 Day 28 visit and prior to the earliest of death in the absence of progression, any evidence of progression, or the last evaluable REiNS assessment if the patient has not died or progressed.

From randomisation date until end of cycle 12 of study intervention
Proportion of Patients With Chronic Target PN Pain Palliation During the Randomised Period
Tidsramme: Baseline and end of cycle 12 of study intervention

Target PN Pain palliation occurs if an improvement of >= 2 in PAINS-pNF chronic target PN pain intensity score and no increase (>=1 in chronic PN pain medication score) in chronic PN pain medication are observed. The PAINS-pNF (Pain Intensity Scale for Plexiform Neurofibroma) chronic target PN pain intensity measures the participants' experience of chronic PN-related pain intensity with score from 0 (no chronic tumor pain) to 10 (worst chronic tumor pain). Baseline PAINS-pNF chronic target PN pain score is defined as the average of the available daily PAINS-pNF chronic target PN pain scores in the screening period, while for Cycle 12, it is defined as the average of the available daily scores for the 28-days cycle up to and including the last day assessment of cycle 12. Chronic PN pain medication was collected through eDiary.

Baseline and end of cycle 12 of study intervention
Time to First Chronic Target PN Pain Palliation (TTPP) in Months During the Randomised Period
Tidsramme: From randomisation date to end of cycle 12 of study intervention

Time to chronic target PN pain palliation (TTPP) is defined as time to first chronic target PN pain palliation. The date of the last day of the cycle will be used for calculating the time to event. TTPP is defined as the duration of time in months from randomisation to the date of the last day of the first cycle where chronic target PN pain palliation is achieved during the randomization period (by the end of cycle 12). The percentage of participants with event are provided. And for comparison of treatment group, the hazard ratio and 95% confidence interval based on COX proportional hazard regression model, and p-value based on unstratified log-rank test are provided.

From randomisation date to end of cycle 12 of study intervention
Percentage of Responders of Decrease in Pain Medication Use From Baseline as Reported Using the eDiary at Cycle 12
Tidsramme: Baseline and end of cycle 12 of study intervention

The eDiary PN pain medications reported daily by the patient will be assigned by medical review to a drug class and analgesic ladder score (0=No analgesia use, 1=Non-opioids use, 2=Neuropathic/other non-typical pain medications use, 3=Weak opioids use, 4=Strong opioids use). In case a combination of one or more drug is reported in a daily diary entry, the strongest drug class and its related daily dose will be selected during the medical adjudication process. The responders of decrease in pain medication use as defined the analgesic ladder score has decreased by >=1 point.

Baseline and end of cycle 12 of study intervention
The Difference of the Means in the Change From Baseline in PII-pNF Pain Interference Total Score at Cycle 12 Between Selumetinib and Placebo
Tidsramme: Baseline and end of cycle 12 of study intervention

The PII-pNF assesses the extent to which PN pain interferes with daily functioning. All items ask the patient to consider the pain related to their PN in the past 7 days. Participants are asked how much their PN pain has made it hard for them to engage in physical activities (e.g., challenging physical activities and self-care), affected their physiological processes (e.g., sleep and energy) or impacted their social-emotional functioning (e.g., enjoyment of activities and mood). Items are rated on a 7-point Likert scale (from 0 = not at all to 6 = completely), and the total score is the mean of the completed items. The mean change from baseline in PII-pNF total score during the randomised period will be calculated using the participant's PII-pNF score at cycle 12 minus the baseline score.

Baseline and end of cycle 12 of study intervention
The Difference of the Means in the Change From Baseline in PROMIS Physical Function Scores at Cycle 12 Between Selumetinib and Placebo
Tidsramme: Baseline and end of cycle 12 study intervention

The Adult Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function items measure self-reported capability rather than the actual performance of physical activities. 3 Items from the PROMIS item bank that map to physical function concepts relevant to patients with symptomatic PN: (1). Does your health now limit you in bending, kneeling, or stooping? (2) How much difficulty do you have doing your daily physical activities, because of your health? (3) To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair? Items are rated on a 5-point rating scale (1-5, the higher the better). A total score was derived by summing up the responses of the three items (Range 3-15). Changes from baseline (CHG) to the end of each cycle in each item and total scores were derived.

Baseline and end of cycle 12 study intervention
The Difference of the Means in Change From Baseline in the Skin Sensations Domain From the PedsQL at Cycle 12 Between Selumetinib and Placebo
Tidsramme: Baseline and end of cycle 12 study intervention

The adult version of the Paediatric Quality of Life Inventory (PedsQL) NF1 Module (NF1 module acute version 3.0 - adult report) can be used to understand the multidimensional nature of NF1 on the HRQoL patients with this disorder and may assist in medical decision making. Skin Sensations domain (3 items) of PedsQL is used. Items are rated on a 5-point Likert scale from 0 ("Never") to 4 ("Almost always") (Higher value represent worse outcome). Items are reverse-scored and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0 (For reversed score, the higher value represent better outcome). Domain scores are calculated by the sum of all the items over the number of items answered if more than 50% of the items. The difference of the means in the change from baseline at Cycle 12 between selumetinib and placebo is presented.

Baseline and end of cycle 12 study intervention
The Difference of Means in the Change From Baseline in EQ-5D Index Score at Cycle 12 Between Selumetinib and Placebo
Tidsramme: Baseline and the end of cycle 12 of study intervention

The EuroQoL five dimensions, five level health state utility index (EQ-5D-5L) is a generic questionnaire that provides a simple descriptive profile of health and a single index value for health status for economic appraisal (EuroQoL 2019). The EQ-5D-5L questionnaire comprises 6 questions that cover 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) over 5 levels of increasing severity of problems ("no" "slight" "moderate" "severe" and "extreme"). Participants indicate their current health state by selecting the most appropriate level in each of the 5 dimensions. The EQ-5D profile is converted into a weighted health state utility value, termed the EQ-5D index that represents the comparative value of health states (the index score generally ranges from negative to 1.0, the higher the score, the better). The difference of the means in the change from baseline of index score at cycle 12 between selumetinib and placebo is presented.

Baseline and the end of cycle 12 of study intervention
The Difference of Means in Change From Baseline in EQ-VAS Score at Cycle 12 Between Selumetinib and Placebo
Tidsramme: Baseline and the end of cycle 12 of study intervention

The EuroQoL five dimensions, five level health state utility index (EQ-5D-5L) developed by the EuroQoL Group, is a generic questionnaire that provides a simple descriptive profile of health and a single index value for health status for economic appraisal (EuroQoL 2019). The EQ-5D-5L questionnaire comprises 6 questions that cover 5 dimensions of health and also assess their health today using the EQ-VAS, which ranges from 0 (worst imaginable health) to 100 (best imaginable health). The difference of the means in the change from baseline of EQ-VAS score at cycle 12 between selumetinib and placebo is presented.

Baseline and the end of cycle 12 of study intervention
Plasma Concentrations (ng/mL) of Selumetinib - Multiple Dose Cycle 1, Day 8
Tidsramme: Pre-dose and 0.5, 1.5, 3, 8, 8 hours after selumetinib single dose on the 8th day of study treatment (Cycle 1 Day 8).

The geometric mean and geometric coefficient of variance (CV) % of the plasma concentrations (ng/mL) of selumetinib for multiple dose of cycle 1 day 8 are presented.

Pre-dose and 0.5, 1.5, 3, 8, 8 hours after selumetinib single dose on the 8th day of study treatment (Cycle 1 Day 8).
Plasma Concentrations (ng/mL) of N-desmethyl Selumetinib - Multiple Dose Cycle 1, Day 8
Tidsramme: Pre-dose and 0.5, 1.5, 3, 6, 8 hours after selumetinib single dose on the 8th day of study treatment (Cycle 1 Day 8).

The geometric mean and geometric coefficient of variance (CV) % of the plasma concentrations (ng/mL) of N-desmethyl selumetinib for multiple dose of cycle 1 day 8 are presented.

Pre-dose and 0.5, 1.5, 3, 6, 8 hours after selumetinib single dose on the 8th day of study treatment (Cycle 1 Day 8).
Pharmacokinetic Parameters of Selumetinib Including AUC(0-6), AUC(0-8), AUC(0-12) , and AUClast - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameters of selumetinib including AUC(0-6) (h* ng/mL), AUC(0-8) (h* ng/mL), AUC(0-12) (h* ng/mL), AUClast (h* ng/mL), are summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
Pharmacokinetic Parameters of Selumetinib Including Tmax and Tlast - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameters of selumetinib including tmax (h) and tlast (h) are summarized and presented as median, and full range (minimum and maximum).

Cycle 1 Day 8
The Pharmacokinetic Parameters of N-desmethyl Selumetinib Including AUC(0-6), AUC(0-8), AUC(0-12) , and AUClast - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameters of N-desmethyl selumetinib including, AUC(0-6) (h* ng/mL), AUC(0-8) (h* ng/mL), AUC(0-12) (h* ng/mL), AUClast (h* ng/mL) are summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
The Pharmacokinetic Parameters of N-desmethyl Selumetinib Including Tmax and Tlast - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameters of N-desmethyl selumetinib including tmax (h) and tlast (h) are summarized and presented as median and full range (minimum and maximum).

Cycle 1 Day 8
Pharmacokinetic Parameter of Selumetinib Including Cmax - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameter of selumetinib including Cmax (ng/mL) is summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
Pharmacokinetic Parameter of Selumetinib Including CL/F - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameter of selumetinib including CL/F (L/h) is summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
Pharmacokinetic Parameters of Selumetinib Including Vss/F - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameter of selumetinib including Vss/F (L) is summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
The Pharmacokinetic Parameter of N-desmethyl Selumetinib Including Cmax - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameter of N-desmethyl selumetinib including Cmax (ng/mL) is summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8
The Pharmacokinetic Parameters of N-desmethyl Selumetinib Including MPAUC and MPCmax - Multiple Dose Cycle 1, Day 8
Tidsramme: Cycle 1 Day 8

The pharmacokinetic parameters of N-desmethyl selumetinib include MPAUC (ratio), and MPCmax (ratio) are the metabolite (N-desmethyl selumetinib) to parent (selumetinib) ratios of the AUC (based on either AUC(0-6) or AUC(0-8) depending on which has the most reportable values) and Cmax values, respectively. Higher values indicate higher relative concentrations of the metabolite; there is no optimal threshold. And they are summarized and presented as Geometric mean and geometric coefficient of variance (CV) %.

Cycle 1 Day 8

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Alice P. Chen, MD, National Cancer Institute (NCI)

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. november 2021

Primær færdiggørelse (Faktiske)

5. august 2024

Studieafslutning (Anslået)

15. februar 2029

Datoer for studieregistrering

Først indsendt

14. maj 2021

Først indsendt, der opfyldte QC-kriterier

7. juni 2021

Først opslået (Faktiske)

14. juni 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • D134BC00001
  • 2020-005607-39 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .